EGFR Tests Market Report: Quantitative Trends, Regulatory Dynamics, and Future Projections

Dublin, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The "EGFR Tests Market Size (Value, Volume, ASP) by Segments, Share, Trend and SWOT Analysis, Regulatory and Reimbursement Landscape, Procedures, and Forecast to 2033" report has been added to's offering.

In the ever-evolving landscape of In Vitro Diagnostics, a comprehensive market analysis has been unveiled, shedding light on the EGFR Tests Market's size, segments, trends, and regulatory landscape.

The report is a groundbreaking tool that offers valuable insights into the market's quantitative trends, regulatory dynamics, and future projections.

The report delves into the profound impact of the COVID-19 pandemic on the EGFR Tests Market, particularly for the year 2020 and beyond. In the realm of global healthcare, lung cancer stands as the second most common cancer among men and the third most prevalent among women.

Lung cancer, with approximately 2.0 million new cases reported globally in 2018, has become a critical concern. A primary risk factor is cigarette smoking, attributing around 80% of male and 45% of female lung cancer cases worldwide to smoking habits.

Central to the report is the Epidermal Growth Factor Receptor (EGFR), a pivotal member of the receptor tyrosine kinase family. Its role in cellular processes like proliferation, invasion, metastasis, and apoptosis inhibition is paramount. EGFR also emerges as a vital biomarker in Non-Small Cell Lung Cancer (NSCLC).

Within NSCLC, EGFR mutations frequently cluster within the tyrosine kinase domain. These mutations, such as in-frame deletions in exon 19 and the exon 21 point mutation (L858R), underline over 85% of known mutations. Notably, these mutations correlate significantly with positive responses to EGFR therapies like gefitinib, erlotinib, afatinib, and icotinib.

The report segments EGFR tests, encompassing Immunohistochemistry, Sanger Sequencing, Nucleic Acid Amplification Tests (NAATs), and Other Tests (ISH and Mass Array). Spanning 39 countries, each market model features procedure volumes and epidemiology-based indications. Transparency is enhanced through interactive Excel deliverables showcasing data such as installed base, sales volumes, average prices, market size, and company rankings. Contextual qualitative insights further enrich the quantitative data.

The report encapsulates:

  • In-depth analysis of current and evolving EGFR Tests Market, highlighting key trends.
  • Annualized revenue projections and outlooks by segment from 2015 to 2033.
  • Market data on units, average prices, and values.
  • Global, regional, and country-specific insights, dissecting trends and dynamics.
  • SWOT analysis, offering a comprehensive view of the market's strengths, weaknesses, opportunities, and threats.
  • Competitive dynamics insights and trends shaping the EGFR Tests Market.

The report serves as a conduit to understand the bigger healthcare picture. Its Market Access segment explores reimbursement policies and regulatory landscapes, enriching the understanding of market dynamics.

Key inclusions encompass:

  • Overview of country-specific healthcare systems.
  • Exploration of country-specific reimbursement policies.
  • Examination of country-specific medtech regulatory landscapes.

The report's robust methodologies and sources fuse primary sources from both demand and supply sides. Key Opinion Leaders, alongside real-world data sources like government databases and hospital purchasing records, contribute to trend identification.

Companies covered span the gamut of market players, including F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, and others. Similarly, countries within the report encompass a global scope, from the United States to Saudi Arabia and Argentina.

In a nutshell, the EGFR Tests Market Model offers a unique blend of qualitative and quantitative insights, imperative for:

  • CMO executives charting strategic planning and investment decisions.
  • Sourcing and procurement executives navigating supply base nuances.
  • Private equity investors discerning investment potentials.

Reasons to consider the report:

  • Understand COVID-19's influence on the EGFR Tests Market.
  • Shape in-licensing and out-licensing strategies with an eye on pipeline products.
  • Craft business strategies aligned with market trends.
  • Drive revenue growth by tapping into key market segments and innovative technologies.
  • Formulate effective sales and marketing strategies informed by competitive dynamics.
  • Track device sales from 2015 to 2033.
  • Optimize sales efforts by identifying high-potential segments.

A selection of companies mentioned in this report includes

  • F. Hoffmann-La Roche Ltd
  • Qiagen NV
  • Agilent Technologies Inc
  • Illumina Inc
  • Thermo Fisher Scientific Inc
  • Abbott Laboratories
  • NimaGen BV
  • Mesa Laboratories Inc
  • New England Biolabs Inc
  • Amoy Diagnostics Co Ltd
  • Panagene Inc

For more information about this report visit

Source: GlobalData

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Contact Data